BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23379261)

  • 1. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells.
    Li Y; Yuan YY; Meeran SM; Tollefsbol TO
    Mol Cancer; 2010 Oct; 9():274. PubMed ID: 20946668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
    Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
    Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
    Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
    Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
    Vesuna F; Lisok A; Kimble B; Domek J; Kato Y; van der Groep P; Artemov D; Kowalski J; Carraway H; van Diest P; Raman V
    Oncogene; 2012 Jul; 31(27):3223-34. PubMed ID: 22056872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
    Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
    Zhou Q; Atadja P; Davidson NE
    Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice.
    Mai Z; Blackburn GL; Zhou JR
    Carcinogenesis; 2007 Jun; 28(6):1217-23. PubMed ID: 17234721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
    Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
    Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
    Mai Z; Blackburn GL; Zhou JR
    Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
    Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
    Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.